Chandler Chicco Launches Multiplatform Content Group

NEW YORK, Sept. 18, 2012 /PRNewswire/ -- Chandler Chicco Companies (CCC), a global health communications group and part of inVentiv Health, Inc., announced today the creation of a Multiplatform Content Group (MCG) with masterful storytelling know-how and expertise in the science of communications to help clients capture attention and move audiences to action.

"Specific knowledge of strategic communications and the skills of the storyteller are needed today to transform data and information into great content that will be heard, acted upon and remembered," said Lisa Stockman, Managing Director of CCC New York.  "As we expand the channels and platforms we use in an increasingly wired world, it becomes ever clearer that the heart of our work is the narrative."

A constant stream of words and data funneled through email, Facebook, Twitter, texts, newsreaders and dozens of other digital and traditional platforms means the average person processes content equivalent to a small novel every day.  Meanwhile, the traditional expert middlemen who controlled and interpreted information have been removed.

"As technology evolves from Gutenberg to Zuckerberg, our jobs as communicators evolve. Now, we must provide context and framework to explain the stunning swirl of information that surrounds us.  We need to provide a narrative story that entertains, explains, informs and touches the heart," said Sydney Rubin, a former reporter and senior counselor who will lead the group.  "George Bernard Shaw said, 'The single biggest problem in communications is the illusion that it has taken place,' and that was decades before the Internet. Creating effective communications today requires a whole new level of expertise."

Underpinning MCG's storytelling expertise are insights from research into the science of communications.  Over the last decade, an unprecedented amount of data has emerged from research in neuroscience and psychology using technologies like functional magnetic resonance and eye tracking.  This data provides new insights into how people receive, process and respond to information.  Research in anthropology and behavioral economics also has enabled the creation of more targeted, powerful content.  Data is no longer something just to be explained, it is the engine behind content strategy and development.

The MCG team -- including a former pharma beat reporter from Businessweek, two correspondents from The Associated Press, a science writer and podcaster from Scientific American, a financial writer from Institutional Investor and others – brings decades of professional experience to enhancing business communications.  All are masters in the craft of brand journalism, creating interactive, data-driven narratives that hit the desired target. 

Members of the MCG team recently have created a multi-part talk show on YouTube for disease education, a monthly corporate comic strip, commentaries for The Huffington Post, editorials for New York City and Boston papers, bylines for magazine features, digital and traditional annual reports, speeches, website content, blog posts and a quarterly glossy magazine.

Using the talents of professional writers, producers and digital content experts, the Multiplatform Content Group offers a full slate of editorial products and services, including:

• content strategy
• branded videos, including corporate videos, talk shows and news magazines
• custom publishing
• animated infographics
• podcasts and podcast scripts
• content aggregation and packaging repurposed content to enhance ROI
• message development for products and corporate reputation
• blogs and microblogs
• slide shows and photo galleries
• speech writing
• feature articles
• opinion-editorials and commentary
• copy for marketing collateral
• multimedia news releases, media communications and advisories

About Chandler Chicco Companies

Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. With an integrated approach to communications, CCC offers best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, marketing and branding, graphic design and multimedia, event production and research and measurement. Companies under the Chandler Chicco umbrella include: Allidura Consumer, Brandtectonics, Biosector 2, Chamberlain Healthcare Public Relations, Chandler Chicco Agency, Chandler Chicco Digital, Chandler Chicco Productions, Determinus, Haas & Health Partner Public Relations, Ingenda Communications, Litmus Medical Marketing & Education, 'nition Design, SanCom Creative Communication Solutions (CCS), and SharedVoice PR.

CCC is part of inVentiv Health, Inc., with companies based in New York, Los Angeles, Washington, London, Paris, Shanghai and Eltville (Frankfurt), as well as global healthcare network operations in 40 markets. For more information, visit www.chandlerchiccocompanies.com.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced  and future acquisitions; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

SOURCE Chandler Chicco Companies